Ultrasensitive Biomarkers for Neurodegenerative Disease: Clinical and Diagnostic Advances
Time: 11:15 am
day: Conference Day One
Details:
New translational ultrasensitive biomarkers that can help define and categorize
neurodegenerative diseases. Use in clinical trials and Dx applications
- Performance characteristics of Simoa-based LDT testing programs utilizing ultrasensitive neurodegeneration biomarkers
- Analytical and clinical sensitivity of Alzheimer’s disease blood-based biomarkers (pTau217 and Multimarker panels)
